Shanghai Henlius Biotech, Inc. (HENLIUS) filed its monthly return for the period ended 30 June 2026, detailing an increase in both authorised and issued share capital driven by employee incentive plans, while confirming continued compliance with Hong Kong’s public-float requirements.
Authorised Share Capital • H-share authorisation rose by 1.71 million shares to 347.79 million, each with a par value of RMB1. • Unlisted ordinary shares remained unchanged at 197.42 million. • Total authorised share capital now stands at 545.21 million shares.
Issued Share Capital and Public Float • H-shares in issue climbed by 1.71 million to 347.79 million, entirely attributable to employee incentive exercises and vesting. • Unlisted issued shares were steady at 197.42 million. • HENLIUS reported zero treasury shares and confirmed that the public float comfortably satisfies the 18.77 % minimum threshold stipulated at listing.
Equity Incentive Activity 1) 2025 H Share Option Scheme – 5,000 options were exercised at HKD 50.25, generating HKD 0.25 million in proceeds. – 28,750 options lapsed during the month. – Outstanding options declined to 7.68 million, with a further 1.70 million shares still available for future exercise; the scheme’s overall headroom remains 28.09 million shares.
2) 2025 H Share RSU Scheme – 1.71 million RSUs vested and converted into H-shares. – 28,750 RSUs lapsed. – Unvested but granted RSUs total 7.70 million, representing an equivalent number of contingent shares.
Other Capital Movements • The issuer reported no activity in warrants, convertibles, or treasury share transactions during June.
The monthly return was submitted on 6 July 2026 and signed by Director Wenjie Zhang.
Comments